| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/01/2006 | US20060116317 Dyeing keratin material; using ninhydrin material |
| 06/01/2006 | US20060116316 Heterocyclic inhibitors of IRES-mediated translation and methods of use thereof |
| 06/01/2006 | US20060116315 Method of screening agent for improving memory and learning ability |
| 06/01/2006 | US20060115897 Compositions and methods modulating variola and vaccinia virus |
| 06/01/2006 | US20060115854 Acetyl-LDL receptor related proteins and peptides as a biomarker for neurodegenerative disease |
| 06/01/2006 | US20060115852 proteins or polypeptides comprising amino acid sequences, used for diagnosis and therapy of diseases associated with oncogenes, such as transcription and apoptosis |
| 06/01/2006 | US20060115848 Nucleic acid end-labeling reagents |
| 06/01/2006 | US20060115813 Intracellular signaling molecules |
| 06/01/2006 | US20060115811 Cytochrome p450ra1-2 and related proteins |
| 06/01/2006 | US20060115525 Pharmaceutical compositions |
| 06/01/2006 | US20060115522 Pharmaceutical composition |
| 06/01/2006 | US20060115513 Derivatized poly(ester amide) as a biobeneficial coating |
| 06/01/2006 | US20060115491 Vaccine delivery; attaching immunogenic determinant of heterologous polypeptide biodrug to the peptidoglycan microparticle on cell wall of a Gram-positive bacterium; improve the binding by treating the cell wall with acid solution to remove protein, lipotechoic, carbohydrates |
| 06/01/2006 | US20060115490 vaccines, immunogenic compositions; diagnostics, enzymatic studies and targets for antibiotics; for treating Staphylococcus aureus infection |
| 06/01/2006 | US20060115480 Disease treatment via antimicrobial peptide inhibitors |
| 06/01/2006 | US20060115478 Compositions and methods for treating and preventing type-1 diabetes |
| 06/01/2006 | US20060115477 Neuropilin-1 inhibitors |
| 06/01/2006 | US20060115469 Interstitial collagenase molecular motor |
| 06/01/2006 | US20060115468 Dietary supplement for treating and preventing gastrointestinal disorders |
| 06/01/2006 | US20060115467 Treating isomaltase defect/disorders via administration of transglucosidase and one additional carbohydrate-digesting enzyme |
| 06/01/2006 | US20060115463 Composition of fibroblast or chondrocyte cells transfected or transduced with a gene encoding transforming growth factor beta 1 (TGF- beta 1) or bone morphogenetic protein 2 (BMP-2), and chondrocyte cells that have not been transfected with the gene; generating hyaline cartilage at a target site |
| 06/01/2006 | US20060115453 Methods and compositions for treating cellular proliferative diseases |
| 06/01/2006 | US20060115452 Uses of interleukin-18 for treating skin disorders associated with uv radiations |
| 06/01/2006 | US20060115451 Modified cytokines for use in cancer therapy |
| 06/01/2006 | US20060115436 Enzyme containing composition, process of producing said composition and its use |
| 06/01/2006 | US20060115376 Irradiation in presence of stabilizer; preventing degradation |
| 06/01/2006 | DE19910102B4 Proteinkonjugate, Verfahren, Vektoren, Proteine und DNA zu deren Herstellung, deren Verwendung, sowie Arzneimittel und Impfstoffe mit einem Gehalt derselben Protein conjugates, methods, vectors, proteins, and DNA for their preparation, their use, as well as drugs and vaccines containing the same |
| 06/01/2006 | CA2591268A1 In situ method for treatment and repair of meniscal injuries |
| 06/01/2006 | CA2590512A1 Fusion protein comprising a bh3-domain of a bh3-only protein |
| 06/01/2006 | CA2589561A1 Treatment of neurodegenerative diseases by the use of laptm4a |
| 06/01/2006 | CA2589460A1 New peptides useful as dual caspase-2/-6 inhibitors and their biological applications |
| 06/01/2006 | CA2589270A1 Stabilized calcium phosphate complexes |
| 06/01/2006 | CA2588908A1 Induction of neurogenesis and stem cell therapy in combination with copolymer 1 |
| 06/01/2006 | CA2588818A1 Athletic ability enhancing composition |
| 06/01/2006 | CA2588285A1 Glycopeptide antibiotic monomer derivatives |
| 06/01/2006 | CA2587775A1 Plasmin-inhibitory therapies |
| 06/01/2006 | CA2587572A1 Dap-10 and uses thereof |
| 06/01/2006 | CA2586126A1 Novel shuttle vector |
| 06/01/2006 | CA2502479A1 Laminin receptor binding molecule |
| 06/01/2006 | CA2488777A1 Laminin receptor binding molecule |
| 05/31/2006 | EP1662003A2 Paramyxovirus vector for gene transfer to the cardiovascular system |
| 05/31/2006 | EP1661998A2 Antigenic polypeptides, antibodies binding thereto, nucleic acids encoding the antigens, and methods of use |
| 05/31/2006 | EP1661997A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/31/2006 | EP1661995A1 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 05/31/2006 | EP1661994A1 Therapeutic agent for NGF |
| 05/31/2006 | EP1661993A1 SLY1 inhibitors in organ, tissue and cell transplantation |
| 05/31/2006 | EP1661913A1 Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis |
| 05/31/2006 | EP1661912A1 Fusion protein comprising a BH3-domain of a BH3-only protein |
| 05/31/2006 | EP1661909A1 Biologically non-degradable peptide, angiotensin converting enzyme inhibitor, drug and functional food |
| 05/31/2006 | EP1661907A1 A cardio myopeptidin, the production and the use thereof |
| 05/31/2006 | EP1661580A1 Remedy for cartilage-related diseases |
| 05/31/2006 | EP1661579A2 Method for treating diseases associated with changes of qualitative and/ quantitative composition of blood extracellular dna |
| 05/31/2006 | EP1661578A1 Skin ulcer preventive curative agent containing human recombinant hgf |
| 05/31/2006 | EP1661577A1 Therapeutic preparation for hematopoietic disease |
| 05/31/2006 | EP1661566A2 Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
| 05/31/2006 | EP1661557A1 Materials and methods for making improved micelle compositions |
| 05/31/2006 | EP1660686A2 Hpv cd8+ t-cell epitopes |
| 05/31/2006 | EP1660682A2 ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION |
| 05/31/2006 | EP1660660A2 Polypeptides of streptococcus pyogenes |
| 05/31/2006 | EP1660659A2 Gdnf-related neuropeptides |
| 05/31/2006 | EP1660658A2 The use of sirna silencing in the prevention of metastasis |
| 05/31/2006 | EP1660656A2 An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia |
| 05/31/2006 | EP1660628A2 SPLICE VARIANTS OF ErbB LIGANDS, COMPOSITIONS AND USES THEREOF |
| 05/31/2006 | EP1660596A1 Microorganism coating components, coatings, and coated surfaces |
| 05/31/2006 | EP1660532A1 Fusion polypeptides, and use thereof in antivascular tumor therapy |
| 05/31/2006 | EP1660531A2 Novel insulin derivatives |
| 05/31/2006 | EP1660529A2 Modified il-4 mutein receptor antagonists |
| 05/31/2006 | EP1660525A1 Plant-derived peptides harboring water-cleaning and antimicrobial activities |
| 05/31/2006 | EP1660522A2 Pharmaceutical composition with increased bioavailability suitable for the administration of oral retroviral protease inhibitors. process for preparing a concentrate pharmaceutical composition comprising a retroviral protease inhibitor |
| 05/31/2006 | EP1660521A2 Agent derived from tortoise spleen stimulating mammalian hemopoiesis |
| 05/31/2006 | EP1660493A1 Peptidyl heterocyclic ketone derivatives and preparation processes |
| 05/31/2006 | EP1660135A1 Method of treating hepatocellular carcinoma |
| 05/31/2006 | EP1660132A1 Composition comprising a pulmonary surfactant and a pde2 inhibitor |
| 05/31/2006 | EP1660117A2 Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
| 05/31/2006 | EP1660116A1 Method of treating viral infections |
| 05/31/2006 | EP1660115A1 Pharmaceutical combination of g-csf and plgf useful for blood stem cell |
| 05/31/2006 | EP1660114A1 Methods and compositions for treating disorders of the extracellular matrix |
| 05/31/2006 | EP1660113A1 A method of producing an anticoagulation effect |
| 05/31/2006 | EP1660112A2 Orally administered small peptides synergize statin activity |
| 05/31/2006 | EP1660111A1 Collagen hydrolysate |
| 05/31/2006 | EP1660110A2 Therapeutic vaccine compositions for the treatment of type 1 diabetes |
| 05/31/2006 | EP1660099A1 Intravascular delivery of non-viral nucleic acid |
| 05/31/2006 | EP1660098A1 Use of surfactant preparations for the treatment of surgical adhesions |
| 05/31/2006 | EP1660095A2 Tricyclic parp inhibitors |
| 05/31/2006 | EP1660094A2 Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| 05/31/2006 | EP1660080A1 Furanone derivatives |
| 05/31/2006 | EP1660078A1 Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions. |
| 05/31/2006 | EP1660073A2 Hydrophobic drug compositions containing reconstitution enhancer |
| 05/31/2006 | EP1660072A2 Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer |
| 05/31/2006 | EP1660057A2 Combination therapy for the treatment of ocular neovascular disorders |
| 05/31/2006 | EP1660047A1 Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| 05/31/2006 | EP1660039A2 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 05/31/2006 | EP1660036A2 Tricalcium phosphates, their composites, implants incorporating them, and methods for their production |
| 05/31/2006 | EP1660026A2 Treatment for cd5+ b cell lymphoma |
| 05/31/2006 | EP1660017A2 Amino acid prodrugs |
| 05/31/2006 | EP1660014A2 Rage-related methods and compositions for treating glomerular injury |
| 05/31/2006 | EP1660008A2 Therapeutic use of g53135-05(fgf-20) in radiation protection |
| 05/31/2006 | EP1660007A2 Compositions for diabetes treatment and prophylaxis |
| 05/31/2006 | EP1604032A4 Method for detecting prognosis of cancer |
| 05/31/2006 | EP1446122B1 Use of flibanserin in the treatment of sexual desire disorders |